Physician profile
Wayne C Furr
NPI 1316011885
$106,186.26
in general payments reported to CMS, 2019-2025
27 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $52.45 · 2021: $69K · 2022: $36K · 2023: $514 · 2024: $244 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $104,104.59 | 2021-2022 | |
| Abbvie INC. | $404.78 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $352.25 | 2021-2025 | |
| Organon LLC | $164.42 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $150.72 | 2022-2024 | Paragard T 380a, Mara Console |
| Merck Sharp & Dohme LLC | $143.47 | 2019-2021 | |
| Exeltis, USA INC. | $122.88 | 2019-2025 | Slynd |
| Avion Pharmaceuticals | $91.30 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $65.22 | 2022-2025 | |
| Shield Therapeutics INC | $63.87 | 2023-2024 | Accrufer |
| Myriad Women'S Health, INC. | $60.27 | 2023 | Myrisk |
| Astellas Pharma US INC | $54.29 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $45.68 | 2019-2025 | Acessa Provu System, Novasure, Myosure Tissue Removal Device |
| Sumitomo Pharma America, INC. | $45.66 | 2025 | Gemtesa |
| Therapeuticsmd, INC. | $41.93 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aroa Biosurgery Incorporated | $41.56 | 2024 | |
| Medicem INC. | $32.00 | 2023 | |
| Idorsia Pharmaceuticals US INC | $30.53 | 2023 | Quviviq |
| Exact Sciences Corporation | $26.41 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $22.93 | 2025 | Wegovy |
| Minerva Surgical, INC | $21.55 | 2025 | |
| Glaxosmithkline, LLC. | $19.82 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.79 | 2019 | |
| Myovant Sciences INC. | $17.88 | 2022 | |
| Sage Therapeutics, LLC | $16.48 | 2025 | Zurzuvae |
| Pfizer INC. | $15.42 | 2024 | |
| Galderma Laboratories, L.P. | $11.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Furr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.